Weight-Loss Drugs Are Changing. Here’s What to Know: QuickTake

December 24, 2025, 8:22 PM UTC

Weight-loss drugs known as GLP-1s are transforming health care. Some people who struggled for years to shed pounds experience dramatic weight loss on the medications, and there are indications that the drugs have potential to treat diseases beyond obesity.

The drugs also have minted billions of dollars for Eli Lilly & Co. and Denmark’s Novo Nordisk A/S, the two pharmaceutical powerhouses that developed the injected medications. Their rivalry is evolving: A head-to-head study showing Lilly’s Zepbound to be more effective than Novo’s Wegovy gave the Indianapolis-based company an edge in 2025. But Novo appeared poised to recover some ground ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.